TRACKSound
Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy
About this track
We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib. Key topics covered include: The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations The importance of shared decision-making in oncology Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations. #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
From the album
Oncology Brothers: Practice-Changing Cancer Discussions25 tracks · Track 23The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap ...
→




















